The market has climbed 1.0% in the last 7 days and is up 28% over the past 12 months, with earnings forecast to grow by 15% annually. In this dynamic environment, identifying high-growth tech stocks can be crucial for investors looking to capitalize on robust market performance and strong future earnings potential.

Top 10 High Growth Tech Companies In The United States

Click here to see the full list of 250 stocks from our US High Growth Tech and AI Stocks screener.

Let's explore several standout options from the results in the screener.

Alnylam Pharmaceuticals

Simply Wall St Growth Rating: ★★★★★☆

Overview: Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference with a market cap of approximately $35.24 billion.

Operations: Alnylam Pharmaceuticals generates revenue primarily through the discovery, development, and commercialization of RNAi therapeutics, amounting to $2.34 billion. The company focuses on leveraging its proprietary technology to create innovative treatments.

Alnylam Pharmaceuticals is navigating a transformative phase with promising clinical outcomes and strategic R&D investments, positioning it uniquely in the biotech sector. Recent data from the HELIOS-B Phase 3 study underscored vutrisiran's potential in reducing mortality and cardiovascular events by significant margins, marking a pivotal advancement in ATTR amyloidosis treatment. Despite being unprofitable, Alnylam's aggressive R&D spending aligns with its innovation trajectory, evidenced by a substantial 19.3% expected annual revenue growth outpacing the US market forecast of 8.7%. Moreover, earnings are projected to surge by an impressive 65.21% annually over the next three years, highlighting its forward-looking approach amidst industry challenges like high volatility and shareholder dilution over the past year.

• Dive into the specifics of Alnylam Pharmaceuticals here with our thorough health report.

• Learn about Alnylam Pharmaceuticals' historical performance.

Live Nation Entertainment

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Live Nation Entertainment, Inc. operates as a live entertainment company worldwide with a market cap of $23.70 billion (NYSE: LYV).

Operations: Live Nation Entertainment generates revenue primarily from Concerts ($19.72 billion), Ticketing ($3.03 billion), and Sponsorship & Advertising ($1.15 billion). The company operates globally, focusing on live entertainment events and related services.

Live Nation Entertainment, despite a challenging year with a 1.2% decline in earnings, is poised for substantial growth with earnings expected to surge by 29.3% annually. This growth trajectory is bolstered by strategic conference presentations and an expanded partnership with PENN Entertainment, enhancing its live event offerings through loyalty program integrations. Moreover, the company's recent $479.8 million shelf registration signals robust financial planning, aiming to capitalize on the burgeoning demand for live entertainment experiences.

• Click here to discover the nuances of Live Nation Entertainment with our detailed analytical health report.

• Evaluate Live Nation Entertainment's historical performance by accessing our past performance report.

Spotify Technology

Simply Wall St Growth Rating: ★★★★★☆

Overview: Spotify Technology S.A., together with its subsidiaries, provides audio streaming subscription services worldwide and has a market cap of approximately $68.71 billion.

Operations: Spotify generates revenue primarily through its Premium subscription service (€12.68 billion) and Ad-Supported segment (€1.79 billion), offering a diverse range of audio streaming options globally.

Spotify Technology has pivoted impressively, with a recent expansion into video content through partnerships, like the one with Cineverse Corp., enhancing its platform's diversity. This strategic move capitalizes on its substantial user base—over 170 million engaged in video podcasts—potentially reshaping content consumption norms. Financially, Spotify's transformation is underscored by a robust revenue upswing to €3.8 billion in Q2 2024 from €3.2 billion the previous year and a swing to net profits of €274 million from a loss of €302 million. Moreover, R&D investments remain aggressive, aligning with an expected earnings growth of 30% annually and maintaining innovation at the core of its strategy despite no new shares repurchased this quarter under its ongoing buyback plan.

• Take a closer look at Spotify Technology's potential here in our health report.

• Examine Spotify Technology's past performance report to understand how it has performed in the past.

Next Steps

• Explore the 250 names from our US High Growth Tech and AI Stocks screener here.

• Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.

• Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.

Ready To Venture Into Other Investment Styles?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.

• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.

• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NasdaqGS:ALNY NYSE:LYV and NYSE:SPOT.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com